Just one dose of the HPV vaccine Cervarix appears to provide enough of an immune response to protect women from two strains of human papillomavirus (HPV) and ultimately cervical cancer, according to a new study published Monday.
HPV is the most common sexually transmitted infection (STI), according to the U.S. Centers for Disease Control and Prevention (CDC). The infection, transmitted through genital contact, is the primary cause of cervical cancer, which affects about 10,300 women in the United States each year. It causes about 275,000 deaths annually worldwide and is a leading cause of cancer deaths among women in low-income countries, according to the World Health Organization.
“Cervical cancer is a major cause of public health concern, especially in less developed countries where about 85% of cervical cancer occurs,” says study author Mahboobeh Safaeian. “The reason for that is mainly because of lack of screening infrastructure offered.”